National protocol for COVID-19 Vaccine AstraZeneca,

As a new vaccine product, MHRA has a specific interest in the reporting of adverse drug reactions for this product. Off-label use COVID-19 Vaccine AstraZeneca is supplied in the UK in accordance with regulation 174 and did not have a UK marketing authorisation at the time of writing this protocol. ................
................